Dr. Safi Shahda on a Phase Ib Study Investigating BBI-608 for mPDAC

Safi Shahda, MD

"This combination seems to be well-tolerated by patients with manageable toxicity, and overall efficacy for the small group seems to be favorable."

Safi Shahda, MD, assistant professor of Clinical Medicine, Indiana University School of Medicine, discusses a phase Ib study looking at a combination of BBI-608, gemcitabine, and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Shahda says so far, 8 patients from the study have been reported on in terms of efficacy and 18 patients have been reported on in terms of safety. He adds that the combination thus far appears to be tolerable with manageable toxicities.